Exosomes as novel therapeutic nanodevices

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 1, 2006, Pages 31-38

  Delcayre, Alain ^a   Le Pecq, Jean Bernard ^a  

^a ExoThera LLC   (United States)

Author keywords

Exosome display; Exosomes; Immunotherapy; Lactadherin; Nanotechnology

Indexed keywords

CANCER VACCINE; CELL PROTEIN; DENDRITIC CELL VACCINE; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HLA A1 ANTIGEN; HLA A24 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR ANTIGEN; VIRUS ANTIGEN; VIRUS PROTEIN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL STRUCTURE; CELL VACUOLE; CELLULAR IMMUNITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG DETERMINATION; DRUG PURIFICATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; ERADICATION THERAPY; FEASIBILITY STUDY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSTIMULATION; INNATE IMMUNITY; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MELANOMA; NANOTECHNOLOGY; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PROCESS OPTIMIZATION; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS, PHASE I; EXOCYTOSIS; HUMANS; IMMUNOTHERAPY; NANOMEDICINE; SECRETORY VESICLES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 32544454154     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Théry C, Zitvogel Z, Amigorena S: Exosomes: Composition, biogenesis and function. Nat Rev Immunol (2002) 2(8):569-579.
2. Fevrier B, Raposo G: Exosomes: Endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol (2004) 16(4):415-421.
3. Barral AM, von Herrath MG: Exosomes: Specific intercellular nano-shuttles? Curr Immunol Rev (2005) 1(1):1-6.
4. Delcayre A, Shu H, Le Pecq JB: Dendritic cell-derived exosomes in cancer immunotherapy: Exploiting nature's antigen delivery pathway. Expert Rev Anticancer Ther (2005) 5(3):537-547.
5. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci (2000) 113(19):3365-3374.
6. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB: Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods (2002) 270(2):211-226.
7. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Mobius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W: Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem (2003) 278(13):10963-10972.
8. Hemler ME: Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol (2003) 19:397-422.
9. Tarrant JM, Robb L, van Spriel AB, Wright MD: Tetraspanins: Molecular organisers of the leukocyte surface. Trends Immunol (2003) 24(11):610-617.
10. Thery C, Boussac M, Veron P, Ricciardi-Castagnoli P, Raposo G, Garin J, Amigorena S: Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles. J Immunol (2001) 166(12):7309-7318.
11. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C et al: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived exosomes: Results of the first phase I clinical trial. J Transl Med (2005) 3(1):10.
12. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 65(12):5238-5247.
13. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol (2002) 3(12):1156-1162.
14. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, Bonnerot C: Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol (2002) 14(7):713-722.
15. Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB: Exosomes as a tumor vaccine: Enhancing potency through direct loading of antigenic peptides. J Immunother (2003) 26(5):440-450.
16. Andre F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T et al: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 172(4)2126-2136.
17. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med (1998) 4(5):594-600.
18. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 172(4):2137-2146.
19. Aline F, Bout D, Amigorena S, Roingeard P, Dimier-Poisson I: Toxoplasma gondii antigen-pulsed-dendritic cell-derived exosomes induce a protective immune response against T. gondii infection. Infect Immun (2004) 72(7):4127-4137.
20. Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, Amigorena S, Thery C: ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood (2005) 106(1):216-223.
21. Kim SH, Lechman ER, Blanco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD: Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol (2005) 174(10):6440-6448.
22. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein Hsc73. J Cell Biol (1999) 147(3):599-610.
23. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C: TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/ζ complex. J Immunol (2002) 168(7):3235-3241.
24. Pisitkun T, Shen RF, Knepper MA: Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA (2004) 101(36):13368-13373.
25. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC, Lambrecht BN: Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol (2004) 31(1):114-121.
26. Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN: Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol (2004) 164(5):1807-1815.
27. Mears R, Craven RA, Hanrahan S, Totty N, Upton C, Young SL, Patel P, Selby PJ, Banks RE: Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 4(12):4019-4031.
28. Flanagan J, Middeldorp J, Sculley T: Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J Gen Virol (2003) 84(7):1871-1879.
29. Nguyen DG, Booth A, Gould SJ, Hildreth JE: Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J Biol Chem (2003) 278(52):52347-52354.
30. Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P, Abrignani S: Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol (2004) 34(10):2834-2842.
31. Pelchen-Matthews A, Raposo G, Marsh M: Endosomes, exosomes and Trojan viruses. Trends Microbiol (2004) 12(7):310-316.
32. Kramer B, Pelchen-Matthews A, Deneka M, Garcia E, Piguet V, Marsh M: HIV Interaction with endosomes in macrophages and dendritic cells. Blood cells Mol Dis (2005) 35(2):136-142.
33. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, Marme A, Phong MC, Linderkamp O, Skorokhod A, Altevogt P: Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells. Clin Cancer Res (2005) 11(7):2492-2501.
34. Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z: Emission of membrane vesicles: Roles in complement resistance, immunity and cancer. Springer Semin Immunopathol (2005) 27(3):375-387.
35. Laulagnier K, Vincent-Schneider H, Hamdi S, Subra C, Lankar D, Record M: Characterization of exosome subpopulations from RBL-2H3 cells using fluorescent lipids. Blood Cells Mol Dis (2005) 35(2):116-121.
36. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 7(3):297-303.
37. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 360(9329):295-305.
38. Taylor DD, Gercel-Taylor C: Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer (2005) 92(2):305-311.
39. Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP: Tumor exosomes expressing Fas ligand mediate CDB+ T-cell apoptosis. Blood Cells Mol Dis (2005) 35(2):169-173.
40. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ: Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer (2005) 113(5):752-760.
41. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM: Membrane microparticles: Two sides of the coin. Physiology (Bethesda) (2005) 20:22-27.
42. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH et al: A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 3(1):9.
43. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T: Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev (22) 188:51-64.
44. Adams M, Navabi H, Croston D, Coleman S, Tabi Z, Clayton A, Jasani B, Mason MD: The rationale for combined chemo/immunotherapy using a toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine (2005) 23(17-18):2374-2378.
45. Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, Jasani B, Bailey-Wood R. Wilson K, Tabi Z, Mason MD, Adams M: Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis (2005) 35(2):149-152.
46. Patel S, Mehta-Damani A, Shu H, Le Pecq JB: An analysis of variability in the manufacturing of dexosomes: Implications for development of an autologous therapy. Biotechnol Bioeng (2005) 92(2):238-249.
47. Le Pecq JB: Dexosomes as a therapeutic cancer vaccine: From bench to bedside. Blood Cells Mol Dis (2005) 35(2):129-135.
48. Paz P, Paranjpe G, Villaflor G, Hsu DH, Le Pecq JB: A validated potency assay for dexosomes, a novel acellular product for cancer therapy. J Immunother (2004) 27(6):S28-S29.
49. Stubbs JD, Lekutis C, Singer KL, Bui A, Yuzuki D, Srinivasan U, Parry G: cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to Factor VIII-like sequences. Proc Natl Acad Sci USA (1990) 87(21):8417-8421.
50. Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y, Nagata S: Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science (2004) 304(5674):1147-1150.
51. Andersen MH, Graversen H, Fedosov SN, Petersen TE, Rasmussen JT: Functional analyses of two cellular binding domains of bovine lactadherin. Biochemistry (2000) 39(20):6200-6206.
52. Veron P, Segura E, Sugano G, Amigorena S, Thery C: Accumulation of MFG-E8/lactadherin on exosomes from immature dendritic cells. Blood Cells Mol Dis (2005) 35(2):81-88.
53. Silvestre JS, Thery C, Hamard G, Boddaert J, Aguilar B, Delcayre A, Houbron C, Tamarat R, Blanc-Brude O, Heeneman S, Clergue M et al: Lactadherin promotes VEGF-dependent neovascularization. Nat Med (2005) 11(5):499-506.
54. Porto-Carreiro I, Fevrier B, Paquet S, Vilette D, Raposo G: Prions and exosomes: From PrPc trafficking to PrPsc propagation. Blood Cells Mol Dis (2005) 35(2):143-148.
55. Srivastava P: Interaction of heat shock proteins with peptides and antigen presenting cells: Chaperoning of the innate and adaptive immune responses. Annu Rev Immunol (2002) 20:395-425.
56. Clayton A, Turkes A, Navabi H, Mason MD, Tabi Z: Induction of heat shock proteins in B-cell exosomes. J Cell Sci (2005) 118(16):3631-3638.
57. Lancaster GI, Febbraio MA: Exosome-dependent trafficking of Hsp70: A novel secretory pathway for cellular stress proteins. J Biol Chem (2005) 280(24):23349-23355.
58. Bausero MA, Gastpar R, Multhoff G, Asea A: Alternative mechanism by which IFN-γ enhances tumor recognition: Active release of heat shock protein 72. J Immunol (2005) 175(5):2900-2912.
59. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol (2003) 3(10):781-790.
60. Cerwenka A, Lanier LL: NKG2D ligands: Unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens (2003) 61(5):335-343.
61. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V: Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 6(5):558-568.
62. Clayton A, Tabi Z: Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis (2005) 34(3):206-213.
63. Siegel RM, Chan FK, Chun HJ, Lenardo MJ: The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol (2000) 1(6):469-474.
64. Green DR, Ferguson TA: The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol (2001) 2(12):917-924.
65. Alonso R, Rodriguez MC, Pindado J, Merino E, Merida I, Izquierdo M: Diacylglycerol kinase α regulates the secretion of lethal exosomes bearing Fas ligand during activation-induced cell death of T lymphocytes. J Biol Chem (2005) 280(31):28439-28450.
66. Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L: Cytoplasmic microvesicular form of Fas ligand in human early placenta: Switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod (2005) 11(1):35-41.
67. Delcayre A, Estelles A, Sperinde J, Roulon T, Paz P, Aguilar B, Villanueva J, Khine S, Le Pecq JB: Exosome display technology: Applications to the development of new diagnostics and therapeutics. Blood Cells Mol Dis (2005) 35(2):158-168.